Close
What would you like to look for?
Site search
2 May 2019

ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced today the completion of a Series A financing of CHF 12.5 million. ALENTIS’ lead program is a humanized monoclonal antibody against a target that plays a key role in the pathology of liver fibrosis and hepatocellular carcinoma (HCC). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the round and were joined by Bpifrance, Schroder Adveq and the German High-Tech Gründerfonds (HTGF). VISCHER AG has been advising Alentis in this financing round and the technology transfer agreement with SATT Conectus.

The team at VISCHER was led by Matthias Staehelin and Christian Wyss (Partner, Corporate) with Nadia Tarolli (Partner,Tax) and Sebastian Flückiger (Associate, Corporate).

Authors